Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYSE: NYXH) is a pioneering health technology company focused on innovative treatments for sleep disordered breathing, particularly Obstructive Sleep Apnea (OSA). This page serves as the definitive source for official updates about their FDA-cleared Genio neurostimulation system, financial developments, and clinical research progress.
Investors and medical professionals will find curated press releases covering regulatory milestones, partnership announcements, and quarterly earnings reports. All content is sourced directly from company filings and verified channels to ensure accuracy.
Key focus areas include updates about international market expansions, clinical trial outcomes for OSA therapies, and technological enhancements to the Genio platform. Bookmark this page to stay informed about Nyxoah's progress in developing patient-centric solutions for chronic sleep conditions.
Nyxoah reported its first half 2021 financial results, highlighting gross proceeds of $97.8 million from its Nasdaq IPO and €355 thousand in revenue, a notable increase from zero in the same period last year. The company is actively expanding its commercial presence in Germany, reporting 12 active accounts in Q2, up from 2 in Q1 2021. However, it recorded a net loss of €12.6 million compared to €4.3 million in the previous year, attributed mainly to heightened operational expenses across various departments. The cash position improved to €79.2 million.
Nyxoah has announced the appointment of Rita Johnson-Mills as an Independent Director to its Board, effective immediately. Her extensive background includes over 30 years in healthcare, notably as CEO of UnitedHealthcare Community Plan of Tennessee. The Chairman, Robert Taub, highlighted her experience and governance expertise as vital for Nyxoah's growth in the healthcare industry. Johnson-Mills aims to enhance Nyxoah's board diversity and strengthen its presence in the U.S. market, while the company focuses on innovative solutions for Obstructive Sleep Apnea treatment.
Nyxoah SA (Nasdaq: NYXH) announced its plan to release financial results for the first half of 2021 on August 31, 2021, after US markets close. A conference call will be held on September 1, 2021, at 3:00 p.m. CET to discuss these results. The company focuses on innovative solutions for treating Obstructive Sleep Apnea (OSA) and has made progress with its Genio® system, which received European CE Mark approval in 2019. Nyxoah is currently conducting pivotal studies for FDA approval and further research on the therapy's long-term efficacy.
On July 19, 2021, Nyxoah SA (NASDAQ: NYXH) announced a transparency notification from BNP Paribas Asset Management SA, revealing a passive downward crossing of the 3% threshold in voting rights. As of July 7, 2021, BNP Paribas held 696,562 shares, equivalent to 2.79% of total voting rights (25,002,609). The notification indicates changes in shareholding but does not indicate any active trading or strategic decisions impacting the company’s operations.
Nyxoah SA, a medical technology company, announced on July 14, 2021, it received a transparency notification from Deerfield Partners, L.P. The notification, received on July 12, detailed that Deerfield acquired 899,300 shares on July 7, 2021, crossing the 3% voting rights threshold, now holding 3.60% of the total voting rights. This acquisition reflects Deerfield’s growing investment in Nyxoah, indicating confidence in the company’s future prospects.
Nyxoah SA announced the issuance of 435,250 new shares on July 9, 2021, following a capital increase tied to its IPO in the U.S. and the exercise of subscription rights. The total share capital now stands at EUR 4,369,902.59, resulting in 25,437,859 voting rights from ordinary shares. Additionally, there are outstanding rights to subscribe to 927,500 shares through various ESOP warrants.
Nyxoah announced the closing of its initial public offering (IPO) on July 7, 2021. The offering included 2,835,000 ordinary shares priced at $30 per share, accumulating total gross proceeds of $85.1 million. Furthermore, underwriters exercised their option to purchase an additional 425,250 shares, increasing gross proceeds to $97.8 million. The closing of this additional share purchase is anticipated on July 9, 2021, subject to standard conditions. Piper Sandler, Stifel, and Cantor acted as joint book-running managers for this offering.
Nyxoah announced the issuance of 2,835,000 new shares on July 7, 2021, related to a capital increase tied to its initial public offering in the United States. This means the share capital now stands at EUR 4,295,126.64, with a total of 25,002,609 voting rights available. The press release outlines the total number of securities and shares following this increase, including various ESOP Warrants that allow holders to subscribe to additional voting securities.
Nyxoah SA has priced its initial public offering (IPO) in the U.S. at US$ 30 per share, totaling US$ 85.1 million in gross proceeds. The offering includes 2,835,000 ordinary shares, with an option for underwriters to purchase an additional 425,250 shares. The IPO is set to close on July 7, 2021, pending conditions. The shares will begin trading on NASDAQ under the symbol NYXH. This marks a significant step in Nyxoah's mission to develop innovative solutions for Obstructive Sleep Apnea.
Nyxoah SA (Euronext Brussels: NYXH) announced the issuance of 60,000 new shares on June 23, 2021, due to the exercise of subscription rights. The company's capital is now EUR 3,808,073.64. The total number of voting rights is 22,167,609, all of which are ordinary shares. Furthermore, various warrants, including 91 from 2013, 365 from 2016, 319 from 2018, and 550,000 from 2020, provide additional rights to subscribe to further shares.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
